Is there a need for antithrombin III substitution early after burn injury?
The changes in antithrombin III (AT-III) levels in the blood and restitution in coagulation parameters between patients receiving and not receiving AT-III substitution were examined early after burn injury. The study was divided into two parts with a total of 14 consecutive patients (per cent total body surface area (TBSA) > or = 20 per cent). The first six patients were given AT-III substitution when AT-III levels fell below 50 per cent. The second part examined the restitution of the coagulation parameters when the patients (n = 8) obtained AT-III substitution only at extremely low values of AT-III. The decline in AT-III observed occurred in parallel to the permeability changes and the haemodilution normally seen secondarily to the initial fluid rescucitation. The observed changes in the coagulation parameters were modest and no hepatic dysfunction was noted. In addition, no differences of the restitution in these coagulation parameters were noted between the substituted and non-substituted groups. These results suggest that changes in AT-III early after burn injury depend mainly on factors other than an ongoing disseminated coagulation process. Probable causes are increased capillary leak and haemodilution. Our results suggest that substitution of AT-III in the early postburn period, on the assumption that low levels alone indicate ongoing coagulation, is not warranted.
Danielsson
P
P
Department of Plastic Surgery, Hand Surgery & Burns, University Hospital Linköping, Sweden.
Nilsson
L
L
Nettelblad
H
H
Sjöberg
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000378:metabolism; D000990:Antithrombin III / Q000378:metabolism / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D002056:Burns / Q000097:blood / Q000628:therapy*; D002648:Child; D005260:Female; D005342:Fibrinolysis; D006438:Hemodilution; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011446:Prospective Studies; D011486:Protein C / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000378:metabolism / Q000627:therapeutic use*
D000925:Anticoagulants; D011486:Protein C; D015842:Serine Proteinase Inhibitors; D000990:Antithrombin III